A prospective study of lipoprotein(a) and risk of coronary heart disease among women with type 2 diabetes

Diabetologia

Volumn 48, Issue 8, 2005, Pages 1469-1476

  Shai, I ^a,b   Schulze, M B ^a   Manson, J E ^a,c   Stampfer, M J ^a,c   Rifai, N ^d   Hu, F B ^a,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Coronary heart disease; Follow up; Lipoprotein(a); Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN B100; BIOLOGICAL MARKER; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; RISK ASSESSMENT; SMOKING;

ADULT; AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; COHORT STUDIES; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIFE STYLE; LIPOPROTEIN(A); MIDDLE AGED; PROSPECTIVE STUDIES; SMOKING; SURVIVAL; TRIGLYCERIDES;

EID: 23844453344     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-1814-3     Document Type: Article

References (35)

1. Milionis HJ, Winder AF, Mikhailidis DP (2000) Lipoprotein (a) and stroke. J Clin Pathol 53:487-496
2. Danesh J, Collins R, Peto R (2000) Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102:1082-1085
3. Gazzaruso C, Garzaniti A, Falcone C et al (2003) Lipoprotein (a), apolipoprotein(a) polymorphism and restenosis after intracoronary stent placement in Type 2 diabetic patients. J Diabetes its Complicat 17:135-140
4. Maser RE, Usher D, Becker DJ et al (1993) Lipoprotein(a) concentration shows little relationship to IDDM complications in the Pittsburgh Epidemiology of Diabetes Complications Study cohort. Diabetes Care 16:755-758
5. Hiraga T, Kobayashi T, Okubo M et al (1995) Prospective study of lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes. Diabetes Care 18:241-244
6. Haffner SM (2004) American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 27 [Suppl 1]:S68-S71
7. Hernandez C, Chacon P, Garcia-Pascual L, Simo R (2001) Differential influence of LDL cholesterol and triglycerides on lipoprotein(a) concentrations in diabetic patients. Diabetes Care 24:350-355
8. Bartens W, Rader DJ, Talley G, Brewer HB (1994) Decreased plasma levels of lipoprotein(a) in patients with hypertriglyceridemia. Atherosclerosis 108:149-157
9. Werba JP, Safa O, Gianfranceschi G, Michelagnoli S, Sirvatori CR, Franceschini G (1993) Plasma triglycerides and lipoprotein (a): inverse relationship in a hyperlipidemic Italian population. Atherosclerosis 101:203-207
10. Hiraga T, Okubo M, Koboyashi T, Nakanishi K, Sugimoto T, Murase T (1993) Serum lipoprotein(a) levels differ in different phenotypes of primary hyperlipoproteinemia. Metabolism 42:1327-1330
11. National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057
12. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Diabetes Care 20:1183-1197
13. Manson JE, Rimm EB, Stampfer MJ et al (1991) Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet 338:774-778
14. Rose GA, Blackburn H, Gillum RF, Prineas RJ (1982) Cardiovascular survey methods. World Health Organization, Geneva
15. Stampfer MJ, Willett WC, Speizer FE et al (1984) Test of the National Death Index. Am J Epidemiol 119:837-839
16. Marcovina SM, Albers JJ, Scanu AM et al (2000) Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 46:1956-1967
17. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE (2004) Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53:693-700
18. Chang J, Hoke C, Ettinger B, Penerian G (1998) Evaluation and interference study of haemoglobin A1c measured by turbidimetric inhibition immunoassay. Am J Clin Pathol 109:274-278
19. Stein JH, Rosenson RS (1997) Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med 157:1170-1176
20. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486-2497
21. Scanu AM, Edelstein C (1965) Kringle-dependent structural and functional polymorphism of apolipoprotein(a). Biochim Biophys Acta 1256:1-12
22. Reblin T, Rader DJ, Beisiegel U, Greten H, Brewer HB Jr (1992) Correlation of apolipoprotein(a) isoproteins with Lp(a) density and distribution in fasting plasma. Atherosclerosis 94:223-232
23. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH (1992) Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein (a) concentrations. J Clin Invest 90:52-60
24. Pai JK, Curhan GC, Cannuscio CC, Rifai N, Ridker PM, Rimm EB (2002) Stability of novel plasma markers associated with cardiovascular disease: processing within 36 hours of specimen collection. Clin Chem 48:1781-1784
25. Kronenberg F, Trenkwalder E, Dieplinger H, Utermann G (1996) Lipoprotein(a) in stored plasma samples and the ravages of time. Why epidemiological studies might fail. Arterioscler Thromb Vasc Biol 16:1568-1572
26. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U (1989) Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 9:579-592
27. Gaubatz JW, Heideman C, Gotto AM Jr, Morrisett JD, Dahlen GH (1983) Human plasma lipoprotein [a]: structural properties. J Biol Chem 258:4582-4589
28. Rand ML, Sangrar W, Hancock MA et al (1998) Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscler Thromb Vasc Biol 18:1393-1399
29. Schachinger V, Halle M, Minners J, Berg A, Zeiher AM (1997) Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation. J Am Coll Cardiol 30:927-934
30. Craig WY, Ledue TB (1992) Lipoprotein(a) and the acute phase response. Clin Chim Acta 210:231-232
31. Emanuele N, Azad N, Abraira C et al (1998) Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Arch Intern Med 158:2485-2490
32. Gonbert S, Malinsky S, Sposito AC et al (2002) Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis 164:305-311
33. Marcovina SM, Kennedy H, Bittolo Bon G et al (1999) Fish intake, independent of apo(a) size, accounts for lower plasma lipoprotein(a) levels in Bantu fishermen of Tanzania: the Lugalawa Study. Arterioscler Thromb Vasc Biol 19:1250-1256
34. Carlson LA, Hamsten A, Asplund A (1989) Pronounced lowering of serum lipid levels of lipoprotein(a) in hyperlipidemic subjects treated with nicotinic acid. J Intern Med 226:271-276
35. Berglund L, Carlström K, Stege R et al (1996) Hormonal regulation of serum lipoprotein(a) levels: effects of parenteral administration of estrogen or testosterone in males. J Clin Endocrinol Metab 81:2633-2637